Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial

Colorectal Neoplasms Clinical Trial

— ImmunoPeCa  

Official title:

Phase I/II Trial of MOC31PE Immunotoxin in Peritoneal Carcinomatosis From Colorectal Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02219893
• Other study ID #: ImmunoPeCa Trial
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: August 8, 2014
• Last updated: May 24, 2017
• Start date: August 2014
• Est. completion date: December 10, 2016

Study information

• Verified date: May 2017
• Source: Oslo University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is through a phase I/II clinical trial to assess the safety and toxicity of intraperitoneally administered MOC31PE immunotoxin, given on the 1.postoperative day after cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for peritoneal metastases from colorectal cancer (CRC).

Description:

MOC31PE is an immunotoxin that has previously been evaluated in a phase I clinical study involving patients with advanced EpCAM positive carcinoma to assess the safety and tolerability profile and the pharmacokinetic behavior of the compound. In this study, the compound was administered intravenously and was well tolerated. MOC31PE will now be evaluated on the same parameters in a new phase I/II clinical trial, where the drug will be administered intraperitoneally to patients with peritoneal metastases from EpCAM positive colorectal carcinomas.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: December 10, 2016
• Est. primary completion date: December 10, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Histologically verified EpCAM positive colorectal cancer

• Ambulatory with Eastern Cooperative Oncology Group (ECOG) performance status 0-1 at the time of surgery

• At least 18 years of age

• Suspected isolated peritoneal carcinomatosis upon radiologic work-up

• Complete cytoreduction at surgery and mitomycin C given as standard HIPEC procedure

• Peritoneal Cancer Index (PCI) = 20

• Laboratory values at inclusion:

• Absolute neutrophil count (ANC) > 1.5 x 10^9/L

• Platelets > 100 x 10^9/L

• Hb > 9g/dL

• Creatinine = 2x upper limit of normal

• Bilirubin < 2.0x the upper limit of normal

• Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) = 2. 5x the upper limit of normal

• Albumin levels > 30 g/L

• International normalised ratio (INR) <1.3

• Signed informed consent and expected cooperation with respect to treatment and follow-up must be obtained and documented according to International Conference of Harmonisation- Good clinical Practice (ICH GCP), and national/local regulations.

Exclusion criteria:

• Other synchronous metastatic lesions. Patients may be included if they have had curative resection of metastatic CRC disease more than 2 years prior to inclusion and have no relapse at this location is detected.

• History of prior other malignant disease the last 3 years, except for adequately treated carcinoma of the cervix or basal or squamous cell skin cancer.

• History of central nervous system (CNS)- or bone metastases

• Significant cardiac or other medical illness that would limit activity or survival, such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia

• History of any liver disease including Hepatitis B or C infection

• Chemotherapy/radiation therapy or major surgery within the last 4 weeks before start of treatment

• BMI > 35

• Pregnant or breast-feeding patients

• Alcohol or drug abuse

• Use of drugs that can influence hepatic function (e.g. phenytoin or phenobarbital)

• Use of anticoagulants

• Any reason why, in the opinion of the investigator, the patient should not participate in the study protocol

Related Conditions & MeSH terms

• Carcinoma
• Colorectal Neoplasms

Intervention

Drug:
• MOC31PE Immunotoxin
Patients who meet inclusion criteria will be treated with a single intraperitoneal MOC31PE immunotoxin instillation for 6 hours on the first day after CRS and HIPEC

Locations

Country	Name	City	State
Norway	Oslo University Hospital- The Norwegian Radium Hospital	Oslo

Sponsors (1)

Lead Sponsor	Collaborator
Oslo University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with Adverse Events as a Measure of Safety and Tolerability	Follow-up: 5 years from administration of study drug, or until disease progression	5 years or until disease progression
Secondary	Cmax, Tmax	Measurements will be done at 0, 3, 6, 12, 24, 48 and 72 hours after administration of study drug	8 weeks
Secondary	Neutralizing anti-immunotoxin antibody response	Measurements of neutralizing anti-immunotoxin antibody response will be done at 4 and 8 weeks after administration of study drug	8 weeks
Secondary	Biomarkers of disease recurrence	Serum samples for identification of biomarkers of disease recurrence will be taken at every follow-up for 5 years or until disease progression	5 years or until disease progression
Secondary	Overall survival	Overall survival of all patients will be assessed after 5 years	5 years
Secondary	Disease free survival	Follow up period of 5 years, or until disease progression	5 years